Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Parcesepe, Pietro ^a   Giordano, Guido ^b   Laudanna, Carmelo ^c   Febbraro, Antonio ^b   Pancione, Massimo ^d  

^a UNIVERSITY OF VERONA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF SANNIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; CANCER ASSOCIATED IMMUNE RESISTANCE; COLORECTAL CANCER; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; REVIEW; TUMOR INFILTRATING IMMUNE CELL; TUMOR MICROENVIRONMENT;

EID: 84960976268     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/6261721     Document Type: Review

References (42)

1. J. Gagan and E. M. Van Allen, "Next-generation sequencing to guide cancer therapy, " Genome Medicine, vol. 7, no. 1, article 80, 2015.
2. A. Bardelli and S. Siena, "Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, " Journal of Clinical Oncology, vol. 28, no. 7, pp. 1254-1261, 2010.
3. S. Valastyan and R. A. Weinberg, "Tumormetastasis:molecular insights and evolving paradigms, " Cell, vol. 147, no. 2, pp. 275-292, 2011.
4. A. J. Gentles, A. M. Newman, C. L. Liu et al., "The prognostic landscape of genes and infiltrating immune cells across human cancers, " Nature Medicine, vol. 21, no. 8, pp. 938-945, 2015.
5. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation, " Nature, vol. 454, no. 7203, pp. 436-444, 2008.
6. D. G. DeNardo, M. Johansson, and L. M. Coussens, "Immune cells as mediators of solid tumor metastasis, " Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 11-18, 2008.
7. J. Condeelis and J. W. Pollard, "Macrophages: Obligate partners for tumor cell migration, invasion, andmetastasis, " Cell, vol. 124, no. 2, pp. 263-266, 2006.
8. O. Trédan, C. M. Galmarini, K. Patel, and I. F. Tannock, "Drug resistance and the solid tumor microenvironment, " Journal of the National Cancer Institute, vol. 99, no. 19, pp. 1441-1454, 2007.
9. I. P. Witz, "The tumor microenvironment: the making of a paradigm, " Cancer Microenvironment, vol. 2, supplement 1, pp. S9-S17, 2009.
10. N. Sethi and Y. Kang, "Unravelling the complexity of metastasis-molecular understanding and targeted therapies, " Nature Reviews Cancer, vol. 11, no. 10, pp. 735-748, 2011.
11. B. B. McConnell and V. W. Yang, "The role of inflammation in the pathogenesis of colorectal cancer, " Current Colorectal Cancer Reports, vol. 5, no. 2, pp. 69-74, 2009.
12. H. A. Smith and Y. Kang, "The metastasis-promoting roles of tumor-associated immune cells, " Journal ofMolecular Medicine, vol. 91, no. 4, pp. 411-429, 2013.
13. T. Kitamura, B.-Z. Qian, and J. W. Pollard, "Immune cell promotion of metastasis, " Nature Reviews Immunology, vol. 15, no. 2, pp. 73-86, 2015.
14. M. Pancione, G. Giordano, A. Remo et al., "Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis, " Journal of Immunology Research, vol. 2014, Article ID 686879, 11 pages, 2014.
15. M. De Palma and C. E. Lewis, "Macrophage regulation of tumor responses to anticancer therapies, " Cancer Cell, vol. 23, no. 3, pp. 277-286, 2013.
16. A. Mantovani, T. Schioppa, C. Porta, P. Allavena, and A. Sica, "Role of tumor-associated macrophages in tumor progression and invasion, " Cancer andMetastasis Reviews, vol. 25, no. 3, pp. 315-322, 2006.
17. D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, "Immunogenic cell death and DAMPs in cancer therapy, " Nature Reviews Cancer, vol. 12, no. 12, pp. 860-875, 2012.
18. G. Malietzis, M. Giacometti, R. H. Kennedy, T. Athanasiou, O. Aziz, and J. T. Jenkins, "The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: A systematic review and meta-analysis, " Annals of Surgical Oncology, vol. 21, no. 12, pp. 3938-3946, 2014.
19. D. C. McMillan, "Systemic inflammation, nutritional status and survival in patients with cancer, " Current Opinion in Clinical Nutrition & Metabolic Care, vol. 12, no. 3, pp. 223-226, 2009.
20. D. T. Le, J. N. Uram, H. Wang et al., "PD-1 blockade in tumors with mismatch-repair deficiency, " The New England Journal of Medicine, vol. 372, no. 26, pp. 2509-2520, 2015.
21. J. Barretina, G. Caponigro, N. Stransky et al., "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, " Nature, vol. 483, no. 7391, pp. 603-607, 2012.
22. G. Giordano, A. Febbraro, M. Venditti et al., "Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept, " Gastroenterology Research and Practice, vol. 2014, Article ID 526178, 13 pages, 2014.
23. N. A. Giraldo, E. Becht, R. Remark, D. Damotte, C. Sautès-Fridman, and W. H. Fridman, "The immune contexture of primary and metastatic human tumours, " Current Opinion in Immunology, vol. 27, no. 1, pp. 8-15, 2014.
24. J. P. Väyrynen, A. Tuomisto, K. Klintrup, J. Mäkelä, T. J. Karttunen, and M. J. Mäkinen, "Detailed analysis of inflammatory cell infiltration in colorectal cancer, " British Journal of Cancer, vol. 109, no. 7, pp. 1839-1847, 2013.
25. F. Donskov, "Immunomonitoring and prognostic relevance of neutrophils in clinical trials, " Seminars in Cancer Biology, vol. 23, no. 3, pp. 200-207, 2013.
26. R. A. Droeser, C. Hirt, S. Eppenberger-Castori et al., "High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor, " PLoS ONE, vol. 8, no. 5, Article IDe64814, 2013.
27. C. Tecchio, P. Scapini, G. Pizzolo, and M. A. Cassatella, "On the cytokines produced by human neutrophils in tumors, " Seminars in Cancer Biology, vol. 23, no. 3, pp. 159-170, 2013.
28. A. Snyder, V. Makarov, T. Merghoub et al., "Genetic basis for clinical response to CTLA-4 blockade in melanoma, " The New England Journal ofMedicine, vol. 371, no. 23, pp. 2189-2199, 2014.
29. M. Yadav, S. Jhunjhunwala, Q. T. Phung et al., "Predicting immunogenic tumourmutations by combiningmass spectrometry and exome sequencing, " Nature, vol. 515, no. 7528, pp. 572-576, 2014.
30. S. L. Topalian, C. G. Drake, and D. M. Pardoll, "Immune checkpoint blockade: A common denominator approach to cancer therapy, " Cancer Cell, vol. 27, no. 4, pp. 450-461, 2015.
31. J. A. Joyce and J. W. Pollard, "Microenvironmental regulation of metastasis, " Nature Reviews Cancer, vol. 9, no. 4, pp. 239-252, 2009.
32. L. Larizza, V. Schirrmacher, and E. Pfluger, "Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage, " Journal of Experimental Medicine, vol. 160, no. 5, pp. 1579-1584, 1984.
33. M. Munzarova, L. Lauerova, and J. Capkova, "Are advanced malignant melanoma cells hybrids between melanocytes and macrophages?" Melanoma Research, vol. 2, no. 2, pp. 127-129, 1992.
34. M. B. Maniecki, A. Etzerodt, B. P. Ulhøi et al., "Tumorpromoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells, " International Journal of Cancer, vol. 131, no. 10, pp. 2320-2331, 2012.
35. I. Shabo, H. Olsson, X.-F. Sun, and J. Svanvik, "Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time, " International Journal of Cancer, vol. 125, no. 8, pp. 1826-1831, 2009.
36. I. Shabo and J. Svanvik, "Expression of macrophage antigens by tumor cells, " in Cell Fusion in Health and Disease, vol. 950 of Advances in Experimental Medicine and Biology, pp. 141-150, Springer, Dordrecht, The Netherlands, 2011.
37. G. Steinert, S. Schölch, T. Niemietz et al., "Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer, " Cancer Research, vol. 74, no. 6, pp. 1694-1704, 2014.
38. T. Grimmig, M. Kim, C.-T. Germer, M. Gasser, and A. M. Waaga-Gasser, "The role of FOXP3 in disease progression in colorectal cancer patients, " OncoImmunology, vol. 2, no. 6, Article ID e24521, 2013.
39. J. Stagg, "The double-edge sword effect of anti-CD73 cancer therapy, " OncoImmunology, vol. 1, no. 2, pp. 217-218, 2012.
40. G. Giordano, A. Febbraro, E. Tomaselli et al., "Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer, " Journal of Experimental & Clinical Cancer Research, vol. 34, article 108, 2015.
41. D. I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte, "Coordinated regulation ofmyeloid cells by tumours, " Nature Reviews Immunology, vol. 12, no. 4, pp. 253-268, 2012.
42. C. Sun, S. Hobor, A. Bertotti et al., "Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3, " Cell Reports, vol. 7, no. 1, pp. 86-93, 2014.